Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052171 | 1.00 | DNM1 (0.46) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL28162019 | 1.00 | DNM1 (0.46) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL1491044 | 1.00 | DNM1 (0.46) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL1683483 | 1.00 | DNM1 (0.46) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL2244043 | 1.00 | DNM1 (0.46) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL2120337 | 1.00 | DNM1 (0.46) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL727617 | 0.97 | — | — | |
| SCHEMBL18822343 | 0.97 | — | — | |
| SCHEMBL13369408 | 0.97 | — | — | |
| SCHEMBL2171079 | 0.95 | DNM1 (0.46) | DNM1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504883-B1 | FABRIC TREATMENT COMPOSITIONS WITH ANTIOXIDANT MULTIMERS | PROCTER & GAMBLE (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4504883-A1 | FABRIC TREATMENT COMPOSITIONS WITH ANTIOXIDANT MULTIMERS | The Procter & Gamble Company (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4463534-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | The Procter & Gamble Company (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20230323250-A1 | FABRIC TREATMENT COMPOSITIONS WITH ANTIOXIDANT MULTIMERS | THE PROCTER & GAMBLE COMPANY | 2023-10-12 | — | — | US | disclosed |
| WO-2023196452-A1 | FABRIC TREATMENT COMPOSITIONS WITH ANTIOXIDANT MULTIMERS | THE PROCTER & GAMBLE COMPANY (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023137409-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | THE PROCTER & GAMBLE COMPANY (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | THE PROCTER & GAMBLE COMPANY | 2023-07-13 | — | — | US | disclosed |
| CN-114014845-A | Epoxy group-containing compound, liquid crystal aligning agent, and preparation method and application thereof | 波米科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20110281909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| EP-2215082-B1 | PHTHALAZINE AND PYRIDO[3,4-D]PYRIDAZINE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| US-7884114-B2 | N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide for treatment of allergic rhinitis | GLAXO GROUP LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-20100216799-A1 | PHTHALAZINE AND PYRIDO[3,4-D]PYRIDAZINE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| EP-2215082-A1 | PHTHALAZINE AND PYRIDO Ý3,4-D¨PYRIDAZ INE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-08-11 | — | — | EP | disclosed |
| EP-2185542-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20090270355-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| WO-2009047336-A1 | PHTHALAZINE AND PYRIDO [3,4-D] PYRIDAZ INE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009021965-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216799-A1 | PHTHALAZINE AND PYRIDO[3,4-D]PYRIDAZINE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH1 | DNM1 4047/4885TSHR 490/4885MEN1 1257/4885 |
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | BCAT2, MTR, ASNS | DNM1 1449/4885TSHR 4858/4885MEN1 1094/4885 |
| US-20090270355-A1 | Compounds | CMA1, HRH4, CCL11 | DNM1 2465/4885TSHR 4192/4885MEN1 1338/4885 |
| US-20110281909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | HRH1, HRH2, HRH4 | DNM1 3779/4885TSHR 563/4885MEN1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.